Glucose and insulin abnormalities in patients with heart failure

European Journal of Cardiovascular Nursing

Volumn 10, Issue 2, 2011, Pages 75-87

  Deaton, Christi ^a,b   Mamas, Mamas A ^a   Rutter, Martin K ^a   Gibson, Martin ^c   Bowell, Susie ^b   Byrne, Ruth ^c   Coezy, Kath ^c   Gow, Jennifer ^b   Williams, Sarah ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Abnormal glucose regulation; Diabetes; Heart failure

Indexed keywords

DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; PRIORITY JOURNAL; REVIEW;

GLUCOSE INTOLERANCE; HEART FAILURE; HUMANS; INSULIN RESISTANCE;

EID: 79955978061     PISSN: 14745151     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcnurse.2010.08.007     Document Type: Review

References (86)

1. International Diabetes Federation Diabetes Atlas 2009, Online version: www.diabetesatlas.org/content/europe. Accessed February 2010. 4th Edition.
2. Amato L., Paolisso G., Cacciatore F., Ferrara N., Ferrara P., Canonico S., et al. Congestive heart failure predicts the development of non-insulin-dependent-diabetes mellitus in the elderly. Diab Metab 2008, 23:213-2184. ADA.
3. World Health Organization Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation 1999, World Health Organization, Geneva.
4. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diab Care 2003, 26(11):3160-3167.
5. American Diabetes Association Diagnosis and Classification of Diabetes. Diab Care 2008, 31(Suppl 1):S55-S60.
6. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diab Care 2009, 32(7):1327-1334.
7. Bartnik M., Ryden L., Malmberg K., Ohrvik J., Pyorala K., Standl E., et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart 2007, 93(1):72-77.
8. Bock G., Dalla Man C., Campioni M., Chittilapilly E., Basu R., Toffolo G., et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006, 55(12):3536-3549.
9. Mamas MA, Deaton C, Rutter MK, Yuille M, Williams SG, Ray SG, New J, Gibson M, Neyses L. Impaired glucose tolerance and insulin resistance in heart failure; under-recognised and under-treated? J Card Fail 2010;16(9):761-8.
10. Chacko S., Boesch C.C., Mamas M.A., Gow J., Bowell S., Neyses L. The Finnish diabetes risk score (FINDRISC) predicts impaired glucose tolerance in a heart failure population. Abstract presented at Heart Failure 2009, Nice, France.
11. Houghton A.R., Harrison M., Perry A.J., Evans A.J., Cowley A.J. Endogenous insulin and insulin sensitivity: an important determinant of skeletal muscle blood flow in chronic heart failure?. Eur Heart J 1998, 19:476-480.
12. Quinn L. Mechanisms in the development of type 2 diabetes mellitus. J Cardiovasc Nurs 2002, 16(2):1-16.
13. Rutter M.K., Wilson P.W.F., Sullivan L.M., Fox C.S., D'Agostino R.B., Meigs J.B. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation 2008, 117:1003-1009.
14. Balkau B., Charles M.A. European Group for the Study of Insulin Resistance (EGIR). Comment on the provisional report from the WHO consultation. Diabet Med 1999, 16:442-443.
15. Hajer G.R., van Haeften T.W., Vissaren F.L. Adipose tissue dysfunction in obesity, diabetes and vascular diseases. Eur Heart J 2008, 29:2959-2971.
16. Kostis J.B., Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens 2005, 18:731-737.
17. Grundy S.M. Higher incidence of new-onset diabetes in patients with heart failure. Am J Med 2003, 114:331-332.
18. Paolisso G., De Riu S., Marrazzo G., Verza M., Varricchio M., D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991, 40:972-977.
19. Tenenbaum A., Fisman E.Z. Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. Am J Cardiovasc Drugs 2004, 4:269-280.
20. Drexler H., Riede U., Munzel T., Konig H., Funke E., Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 1992, 85:1751-1759.
21. Sabelis L.W.E., Senden P.J., Te Boekhorst B.C.M., Hulzebos H.J., van de Wiels A., van Haeften T.W., et al. Does physical training increase insulin sensitivity in chronic heart failure patients. Clin Sci 2004, 106:459-466.
22. Kemppainen J., Tsuchida H., Stolen K., Karlsson H., Bjornholm M., Heinonen O.J., et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol 2003, 550:305-315.
23. Hayat S.A., Patel B., Khattari R.S., Malik R.A. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci 2004, 107:539-557.
24. Mamas M.A., Neyses L. Cardiac metabolism; from bench to bedside diabetic cardiomyopathy, a disease of cardiac metabolism?. Recent Advances in Cardiology 2007, 27-39. Royal Society of Medicine Press Ltd, London, UK. D. Rowlands, B. Clarke (Eds.).
25. Kamalesh M., Nair G. Disproportionate increase in prevalence of diabetes among patients with congestive heart failure due to systolic dysfunction. Int J Cardiol 2005, 99(1):125-127.
26. DeGroote P., Lamblin N., Mouquet F., Plichon D., McFadden E., van Belle E., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004, 25:656-662.
27. Dries D.L., Sweitzer N.K., Drazner M.H., Stevenson L.W., Gersh B.J. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001, 38:421-428.
28. Berry C., Brett M., Stevenson K., McMurray J.J.V., Norrie J. Nature and prognostic importance of glucose tolerance and diabetes in acute heart failure. Heart 2008, 94:296-304.
29. MacDonald M.R., Petrie M.C., Varyani F., Ostergren J., Michelson E.L., Young J.B., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. Eur Heart J 2008, 29:1377-1385.
30. Goode K.M., John J., Rigby A.S., Kilpatrick E.S., Atkin S., Bragadeesh T., Clark A.L., Cleland J.G.F. Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart 2009, Online First, published on February 19, 2009. 10.1136/hrt.2008.156646.
31. From A.M., Leibson C.L., Bursi F., Redfield M.M., Weston S.A., Jacobsen S.J., et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006, 119(7). 591-9.l.
32. Komajda M., Hanon O., Hochadel M., Lopez-Sendon J.L., Follath F., Ponikowski P., et al. Contemporary management of octogenarians hospitalised for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009, 30:478-486.
33. Kosiborad M., Inzucchi S.E., Spertus J.A., Wang Y., Masoudi F.A., Havranek E.P., et al. Elevated admission glucose and mortality in elderly patients hospitalised with heart failure. Circulation 2009, 119:1899-1907.
34. O'Meara E., Clayton T., McEntegart M.B., McMurray J.J.V., Pina I.L., Granger C.B., et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2007, 115:3111-3120.
35. Suskin N., McKelvie R.S., Burns R.J., Latini R., Pericak D., Probstfield J., et al. Glucose and insulin abnormalities related to functional capacity in patients with congestive HF. Eur Heart J 2000, 21:1368-1375.
36. Varela-Roman A., Shamagian L.G., Caballero E.B., Ramos P.M., Veloso P.R., Gonzalez-Juanatey J.R. Influence of diabetes on the survival of patients hospitalised with heart failure: a 12-year study. Eur J Heart Fail 2005, 7:859-864.
37. Torp-Pedersen C., Metra M., Charlesworth A., Spark P., Lukas M.A., Poole-Wilson P.A., et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol or Metoprolol European Trial (COMET). Heart 2007, 93:968-973.
38. Gerstein H.C., Swedberg K., Carlsson J., McMurray J.J.V., Michelson E.L., Oloffson B., et al. The Hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalisation for heart failure, or death in patients with chronic heart failure. An analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Arch Intern Med 2008, 168:1699-1704.
39. Tenenbaum A., Motro M., Fisman E.Z., Leor J., Freimark D., Boyko V., et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 2003, 114:271-275.
40. Swan J.W., Anker S.D., Walton C., Godsland I.F., Clark A.L., Leyva F., et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997, 30:527-532.
41. Doehner W., Rauchhas M., Ponikowski P., Godsland I.F., von Haehling S., Okonko D.O., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardioly 2005, 46:1019-1026.
42. Wisniaki N., Taylor W., Lye M., Wilding J.P.H. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005, 91:32-37.
43. Bozkurt B., Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J 2005, 150:1233-1239.
44. Conard M.W., Haddock K., Poston W.S.C., Havranek E., McCullough P., Spertus J., et al. Impact of obesity on the health status of heart failure patients. J Card Fail 2006, 12:700-706.
45. Frankenstein L., Remppis A., Nelles M., Schaelling B., Schellberg D., Katus H., et al. Relation of N-terminal pro-brain natriuretic peptide levels and their prognostic power in chronic stable heart failure to obesity status. Eur Heart J 2008, 29:2634-2640.
46. Sabelis L.W.E., Senden P.J., Zonderland M.L., et al. Determinants of insulin sensitivity in chronic heart failure. Eur J Heart Fail 2003, 4:759-765.
47. MacDonald M.R., Jhund P.S., Petrie M.C., Lewsey J.D., Hawkins N.M., Bhagra S., et al. Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex. A population study of 5.1 million people in Scotland. Circ Heart Fail 2008, 1:234-241.
48. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259.
49. Tribouilloy C., Rusinaru D., Majhoub H., Tartie're J.-M., Kesri-Tartie're L., Godard S., et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart 2008, 94:1450-1455.
50. Held C., Gerstein H.C., Yusuf S., Zhao F., Hilbrich L., Anderson C., et al. Glucose levels predict hospitalisation for congestive heart failure in patients at high cardiovascular risk. Circulation 2007, 115:1371-1375.
51. Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.-J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007, 28:88-136.
52. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J.V., Ponikowski P., Poole-Wilson P.A., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2008, 29:2388-2442.
53. MacDonald M.R., Petrie M.C., Hawkins N.M., Petrie J.R., Fisher M., McKelvie R., et al. Diabetes, left ventricular systolic dysfunction and chronic heart failure. Eur Heart J 2008, 29:1224-1240.
54. White M., Lepage S., Lavoie J., De Denus S., Leblanc M., Gossard D., et al. Effects of combined Candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail 2007, 13:86-94.
55. Ghali J.K., Boehmer J., Feldman A.M., Saxon L.A., Demarco T., Carson P., et al. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 2007, 13:769-773.
56. von Bibra H., Hansen A., Dounis V., Bystedt T., Malmberg K., Ryden L. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 2004, 90:1483-1484.
57. Jarnert C., Landstedt-Hallin L., Malmberg K., Melcher A., Ohrvik J., Persson H., et al. A randomised trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes Mellitus and Diastolic Dysfunction) study. Eur J Heart Fail 2009, 11:39-47.
58. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EAM, Howard BV, Kirkman S, Kosiborod M, Reaven P, Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119(2):351-7.
59. Tahrani A.A., Varughese G.I., Scarpello J.H., Hanna F.W.F. Metformin, heart failure and lactic acidosis: is metformin absolutely contraindicated?. BMJ 2007, 335:508-512.
60. Khurana R., Malik I.S. Metformin: not the bad guy. Heart Jul 2 2009, published online. 10.1136/hrt.2009.173773.
61. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diab Care 2005, 28:2345-2351.
62. Wong A.K.F., Symon R., Adzjali M., Ang D., Choy A.M., Petrie J.R., et al. Metformin in insulin resistant LV dysfunction: a double-blind, placebo controlled trial (Tayside Trial). Heart 2010, 96(suppl. 1):A39-A40.
63. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy: clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008, 51:93-102.
64. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., Krumholz H.M. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583-590.
65. Aguilar D., Bozkurt B., Pritchett A., Petersen N.J., Deswal A. The impact of thiazolidinedione use on outcome in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 2007, 50:32-36.
66. Kaul S., Bolger A.F., Herrington D., Giugliano R.P., Eckel R.H. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 2010, 55:1885-1894.
67. Erdmann E., Wilcox R.G. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impacts of increased risk of heart failure. Eur Heart J 2008, 29:12-20.
68. http://www.theheart.org/article/1096613.do (As rosiglitazone review looms, FDA documents slam RECORD and find significant risks for the drug). Accessed July 2010.
69. Goelher A., Januzzi J.L., Worrell S.S., Osterziel K.J., Gazelle G.S., Dietz R., et al. A systematic meta-analysis of the efficacy and heterogeneity of Disease Management Programs in congestive heart failure. J Card Fail 2006, 12:554-567.
70. McAlister F.A., Stewart S., Ferrua S., McMurray J.J.V. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004, 44:810-819.
71. Ware M.G., Flavell C.M., Lewis E.F., Nohria A., Warner-Stevenson L., Givertz M.M. Heart failure and diabetes: collateral benefit of chronic disease management. Congest Heart Fail 2006, 12:132-136.
72. Lavie C.J., Milani R.V. Obesity and cardiovascular disease: the Hippocrates paradox?. JACC 2003, 42:677-679.
73. Arena R., Myers J., Abella J., Pinkstaff S., Brubaker P., Moore B., et al. Influence of etiology of heart failure on the obesity paradox. Am J Cardiol 2009, 104:1116-1121.
74. Oreopoulos A., Padwal R., Kalantar-Zadeh K., Fonarow G.C., Norris C.M., McAlister F.A. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008, 156:13-22.
75. Evangelista L.S., Moser D.K., Westlake C., Hamilton M.A., Fonarow G.C., Dracup K. Impact of obesity on quality of life and depression in HF patients. Eur J Heart Fail 2006, 8:750-755.
76. Pocock S.J., McMurray J.J.V., Dobson J., Yusuf S., Granger C.B., Michelson E.L., et al. Weight loss and mortality risk in patients with chronic heart failure in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur Heart J 2008, 29:2641-2650.
77. Usefulness of a home-based exercise program for overweight and obese patients with advanced heart failure. Am J Cardiol 2006, 97:886-890.
78. Evangelista L.S., Heber D., Li Z., Bowerman S., Hamilton M.A., Fonarow G.C. Reduced body weight and adiposity with a high-protein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study. J Cardiovasc Nurs 2009, 24:207-215.
79. O'Connor C.M., Whellan D.J., Lee K.L., Keteyian S.J., Cooper L.S., Ellis S.J., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-Action Randomised Controlled Trial. JAMA 2009, 301:1439-1450.
80. Flynn K.E., Pina I.L., Whellan D.J., Lin L., Blumenthal J.A., Ellis S.J., et al. Effects of exercise training on health status of patients with chronic heart failure: HF-ACTION Randomised Controlled Trial. JAMA 2009, 301:1451-1459.
81. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle interventions or metformin. N Engl J Med 2002, 346:393-403.
82. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., HAmalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
83. Nishiyama Y., Minohara M., Ohe M., Hirai Y., Katoh A., Miyamoto T., et al. Effect of physical training on insulin resistance in patients with chronic heart failure. Circulation 2006, 70:864-867.
84. Sabelis L.W.E., Senden P.J., te Boekhorst B.C.M., Huzebos H.J., van de Wiel A., van Haeften T.W., et al. Does physical training increase insulin sensitivity in chronic heart failure patients?. Clin Sci 2004, 106:459-466.
85. Kemppainen J., Stolen K., Kalliokoski K.K., Salo T., Karanko H., Viljanen T., et al. Exercise training improves insulin stimulated skeletal muscle glucose uptake independent of changes in perfusion in patients with dilated cardiomyopathy. J Card Fail 2003, 9:286-295.
86. Solang L., Malmberg K., Ryden L. Diabetes mellitus and congestive heart failure: further knowledge needed. Eur Heart J 1999, 20:789-795.